Page 473 - 73_04

VOL. 73 (4), 1265-1285, 2007 INDIVIDUALIZACIÓN DE CARBOPLATINO EN...

(9) HUITEMA, A.D.R.; MATHÔT, R.A.A.; TIBBEN, M.M.; SCHELLENS, J.H.M.; RODENHUIS,
(10) S. Y BEIJNEN, J.H. (2000) Validation of thecniques for the prediction of car-
(11) boplatin exposure; Application of Bayesian methods. Clin. Pharmacol. Ther.
(12) 67: 621-630.
(13) GORE, M. (2003). Carboplatin Equals Cisplatin: But How Do I Prescribe it? J.
(14) Clin. Oncol. 21:17, 1-3.
(15) KLOFT, C.; SIEGERT, W. Y JAEHDE, U. (2003) Individualised dosing strategy for
(16) high-dose CbPt in patients with germ cell cancer. British Journal of Cancer
(17) 89: 787-794.
(18) NAGAO, S.; FUJIWARAA, K.; IMAFUKU, N.; KAGAWA, R.; KOZUKA, Y.; ODA, T.; MAEHA-
(19) TA, K.; ISHIKAWA, H.; KOIKE, H.; AOTANI, E. Y KOHNO, I. (2005) Difference of
carboplatin clearance estimated by the Cockroft–Gault, Jelliffe, Modified-
(20) Jelliffe, Wright or Chatelut formula. Gynecologic Oncology. 99: 327-333.
SEDERHOLM, C. (2002) Gemcitabine versus Gemcitabine/Carboplatin in Advan-
(21) ced Non-Small-Cell Lung Cancer: Preliminary Findings in a Phase III Trial
od the Swedish Lung Cancer Study Group. Semin. Oncol. 29 (Supl 9) 50-54.
WANG, L.; WU, X.; HUANG, M.; CAI, J.; XU, N. Y LIU, J. (2007) The efficacy and
relationship between peak concentration and toxicity profile of fixed-dose-
rate gemcitabine plus carboplatin in patients with advanced non-small-cell
lung cancer. Cancer Chemother Pharmacol. 60: 211–218.
AMERICAN CANCER SOCIETY. Cancer Facts & Figures 2007. Atlanta: American
Cancer Society 2007.
http://www.ine.es/inebmenu/mnu_salud.htm#5 (Acceso el 22-8-2007).
PFISTER, D.G.; JOHNSON, D.H.; AZZOLI, C.G.; SAUSE, W.; SMITH, T.J.; BAKER, S. JR.;
OLAK, J.; STOVER, D.; STRAWN, J.R.; TURRISI, A.T. Y SOMERFIELD, M.R. (2004)
American Society of Clinical Oncology treatment of unresectable non-small-
cell lung cancer guideline: update 2003. J. Clin. Oncol. 22: 330-353.
DEBALDO, C.; MICHIELS, S.; SYZ, N.; SORIA, J.C.; LE CHEVALIER, T. Y PIGNON, J.P.
(2004) Benefits od adding a drug to a single agent or a 2 –agent chemothe-
rapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA.
292: 470-484.
SEDERHOLM, C.; HILLERDAL, G.; LAMBERG, K.; KÖLBECK, K.; DUFMATS, M.; WEST-
BERG, R. Y GAWANDE, S.R. (2005) Phase III trial of gemcitabine plus carbopla-
tin versus single-agent gemcitabine in the treatment of locally advanced or
metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
J. Clin. Oncol. 23: 8380-8388.
GEORGOULIAS, V.; ARDAVANIS, A.; TSIAFAKI, X.; AGELIDOU, A.; MIXALOPOULOU, P.;
ANAGNOSTOPOULOU, O.; ZIOTOPOULOS, P.; TOUBIS, M.; SYRIGOS, K.; SAMARAS, N.;
POLYZOS, A.; CHRISTOU, A.; KAKOLYRIS, S.; KOUROUSSIS, C.; ANDROULAKIS, N.; SAMO-
NIS, G. Y CHATZIDAKI, D. (2005) Vinorelbine plus cisplatin versus docetaxel plus
gemcitabine in advanced non-small-cell lung cancer: a phase III randomized
trial. J. Clin. Oncol. 23: 2937-2945.
PUJOL, J.L.; BRETON, J.L. ; GERVAIS, R.; REBATTU, P.; DEPIERRE, A.; MORERE, J.F. ;
MILLERON, B. ; DEBIEUVRE, D.; CASTÉRA, D.; BOUQUET, P.J.; MORO-SIBILOT, D.;
LEMARIÉ, E.; KESSLER, R.; JANICOT, H.; BRAUN, D.; SPAETH, D.; QUANTIN, X. Y
CLARY, C. (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in ad-

1283